BioXcel Therapeutics files Chapter 11, sells assets to Teva

Plus: Hawaii's HMSA reverses value-based pay to fee-for-service. The day's rules, money, and enforcement, sourced and tiered below.

Share

Plus: Hawaii's HMSA reverses value-based pay to fee-for-service. The day's rules, money, and enforcement, sourced and tiered below.

American Health Intel
Rules · Money · Medicine · Decoded daily
The Ledger Monday, August 31, 2026
BioXcel Therapeutics files Chapter 11, sells assets to Teva
Plus: Hawaii's HMSA reverses value-based pay to fee-for-service. The day's rules, money, and enforcement, sourced and tiered below.
Deal  Confidence: Medium
BioXcel Therapeutics, a Connecticut drugmaker behind an FDA-approved anti-agitation film for schizophrenia and bipolar disorder, filed Chapter 11 bankruptcy and agreed to sell its entire drug portfolio to Teva.
The deal with Teva, a major generic and specialty drugmaker, pays $57.5 million upfront plus up to $67.5 million more if an expanded at-home use of the drug wins FDA approval, decision expected November 14.
Why it matters
Watch whether the FDA approves expanded at-home use of Igalmi by November 14, 2026; that decision determines how much of the deal's contingent value Teva actually pays out.
Deadline  Confidence: Medium
HMSA, the Blue Cross Blue Shield insurer that covers most of Hawaii, is reversing a value-based payment model for independent primary care doctors back to old-style fee-for-service starting tomorrow.
One rural practice expects to lose 40% of its HMSA patients and $162,000 a year in revenue. A second practice, Hilo Family Medicine, is closing entirely on September 30.
Why it matters
Watch whether more independent Hawaii primary care practices close or shrink their HMSA panels as the transition proceeds toward the January 1, 2027 final deadline.
Also today
Radiology Partners to acquire Everlight Radiology Read
Faro AI raises $37.3M Series B for clinical-trials AI Read
Arintra raises $25M Series B for revenue-assurance AI Read
636
Records
$38.4B
Enforcement
28
Deadlines
166
Rules
Read this issue + the trackers
Pick your field on the site and every story tells you what it means for you.
Reply to this email and tell us what you want covered. We read everything.
We show our work. We score our own calls.
News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe